Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Bumetanide in Heart Failure Patients with Implanted Monitoring Systems
NCT07375212Phase 4Withdrawn
- Sponsor
- Prisma Health
- Start
- Jan 2026
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of bumetanide nasal spray in heart failure (HF), sponsored by Prisma Health. Planned start Jan 2026; status: withdrawn.
02
Drugs
bumetanide nasal spray
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT07375212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07375212.